Bloomage Biotech(SH:688363) 第一财经·2025-07-27 03:46Core Viewpoint - The article discusses allegations of financial fraud against Huaxi Biological (688363.SH) and its controlling shareholder, Huaxi Xinyu Investment Co., Ltd. The company has denied these allegations and claims that the accuser has a history of embezzlement [1][2]. Group 1: Allegations and Responses - A former employee, referred to as Mr. Li, accused Huaxi Biological of financial fraud, including concealing the holding of 30 million shares of Jinzhou Bank and fabricating revenue and inflated expenses in 2017 [1][4]. - Huaxi Biological issued a statement claiming that Mr. Li had previously committed embezzlement and that his allegations are unfounded [1][2]. - The company stated that Mr. Li had reported similar accusations during the IPO review process in 2019, which were investigated and found to be false [2]. Group 2: Financial Practices and Regulatory Actions - Huaxi Xinyu issued exchangeable bonds in May 2017, and the financial data disclosed during this process was later found to be inaccurate, leading to a warning from the Beijing Securities Regulatory Bureau [3]. - The warning was linked to Mr. Li's allegations, as he provided evidence to the regulatory body [4]. - Huaxi Xinyu's financial practices included adjustments to costs and expenses based on actual business conditions, which were reported in compliance with tax regulations [2]. Group 3: Shareholding and Legal Disputes - As of the first quarter of 2025, Huaxi Xinyu holds 283.5 million shares of Huaxi Biological, representing a 58.86% stake [1]. - There have been legal disputes related to the shareholding of Jinzhou Bank, where Huaxi Xinyu was involved in a lawsuit concerning the holding of 30 million shares on behalf of another entity [5].